Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.72 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | POLA1 | P09884 | 2/20 | 0.51 |
| ▸ | POLG | P54098 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pmedap SCHEMBL29571667 | 1.00 | FGFR1 (0.72) | FGFR1SLC22A6POLBCDK1CCNB1 | |
| SCHEMBL2734810 | 0.90 | FGFR1 (0.59) | FGFR1SLC22A6POLBCDK1CCNB1 | |
| SCHEMBL1566036 | 0.89 | FGFR1 (0.63) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL30759944 | 0.89 | FGFR1 (0.63) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL23015054 | 0.88 | SLC22A6 (0.62) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL2607253 | 0.88 | SLC22A6 (0.62) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL29626981 | 0.88 | SLC22A6 (0.62) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL24721834 | 0.87 | FGFR1 (0.56) | FGFR1SLC22A6POLBCDK1CCNB1 | |
| SCHEMBL1567494 | 0.86 | FGFR1 (0.60) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL30824623 | 0.86 | FGFR1 (0.60) | FGFR1SLC22A6POLBPOLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497435-B2 | Multimerization of IL-15/IL-15R-alpha-fc complexes to enhance immunotherapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-16 | — | — | US | claimed |
| US-20230110614-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| EP-4125936-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| US-20220106375-A1 | MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-07 | — | — | US | claimed |
| EP-3908314-A1 | MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY | Memorial Sloan Kettering Cancer Center (US) | 2021-11-17 | — | — | EP | claimed |
| WO-2021194890-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| WO-2020146835-A1 | MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-07-16 | — | — | WO | claimed |
| US-8580753-B2 | Modulation of telomere length in telomerase positive cells and cancer therapy | ALT SOLUTIONS INC. (US) | 2013-11-12 | — | — | US | claimed |
| EP-2223927-A2 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| EP-1532157-A4 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | METABASIS THERAPEUTICS INC (US) | 2009-02-25 | — | — | EP | claimed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| EP-1165570-B9 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | claimed |
| WO-2005090370-A1 | PHARMACOLOGICALLY ACTIVE AGENTS CONTAINING ESTERIFIED PHOSPHONATES AND METHODS FOR USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050192246-A1 | Pharmacologically active agents containing esterified phosphonates and methods for use thereof | US ARMY, SECRETARY OF THE ARMY | 2005-09-01 | — | — | US | claimed |
| EP-1532157-A2 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | Metabasis Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| US-12576103-B2 | Heparin and N-acetylcysteine for the treatment of lung injury | ATOSSA THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-0350287-A2 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | NeXstar Pharmaceuticals, Inc. (US) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | FGFR1 3580/4885SLC22A6 432/4885POLB 84/4885 |
| US-20050192246-A1 | Pharmacologically active agents containing esterified phosphonates and methods for use thereof | PHPT1, PPIP5K2, PHOSPHO1 | FGFR1 592/4885SLC22A6 2751/4885POLB 621/4885 |
| US-12576103-B2 | Heparin and N-acetylcysteine for the treatment of lung injury | SERPINC1, TXNRD2, TXN | FGFR1 2330/4885SLC22A6 1497/4885POLB 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.